Infection Control Today
   
Back To COVID-19 HW USA Infection Control Today Page 
 
  

28.  Eli Lilly Neutralizing Antibodies: Breakthrough for COVID-19 Treatment?
Eli Lilly announced preliminary results to their SARS-CoV-2 neutralizing antibody product, LY-CoV555, which was reported to have spectacular results with a 72% decrease in hospitalizations or ER visits when mildly or moderately symptomatic patients are given the drug within 3 days of diagnosis.
As observed in the Eli Lilly study, those newly diagnosed patients who are obese or have advanced age are the most likely to become hospitalized, and I feel initially this innovative product should be targeted toward these high-risk patients.  Infection Control Today.  Sept. 17, 2020.    Download Original Article

Updated Oct. 8, 2020.   https://www.infectioncontroltoday.com/view/eli-lilly-neutralizing-antibodies-breakthrough-for-covid-19-treatment
   

(1) Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting. News Release. Sept. 16, 2020. https://investor.lilly.com/news-releases/news-release-details/lilly-announces-proof-concept-data-neutralizing-antibody-ly 

(2) Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs. News Release. Oct. 7, 2020. https://investor.lilly.com/news-releases/news-release-details/lilly-provides-comprehensive-update-progress-sars-cov-2 

(3) Spinner CD, Gottlieb SR, Criner GJ, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19A Randomized Clinical Trial. JAMA. Aug. 21, 2020. https://jamanetwork.com/journals/jama/fullarticle/2769871 

(4) Strathdee S and Patterson T. The Perfect Predator: A Scientist's Race to Save Her Husband from a Deadly Superbug: A Memoir. Sept. 17, 2020. https://theperfectpredator.com/